

Rec'd PCT/PTO 30 JUN 2004
PCT/EP 02 / 13092
0/500606 #2



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D 16 JAN 2003

VvIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02075052.7

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



Anmeldung Nr:
Application no.: 02075052.7
Demande no:

Anmeldetag:
Date of filing: 02.01.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

PHARMACIA & UPJOHN S.p.A.
Via Robert Koch, 1.2
20152 Milano
ITALIE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Combined therapy against tumors comprising substituted acryloyl distamycin
derivatives and tyrosine kinase inhibitors

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K31/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

44

44

10

Distamycin A is an antibiotic substance with antiviral and antiprotozoal activity, having a
15 polypyrrole framework [*Nature* 203: 1064 (1964); *J. Med. Chem.* 32: 774-778 (1989)].

15

20

25

- $$\text{H}_2\text{C}=\text{C}(\text{R}_1)\text{C}(=\text{O})\text{NHR}_2 \quad (\text{I})$$

wherein:

R_1 is a bromine or chlorine atom;

R_2 is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and

- a protein kinase inhibitor.

5

The present invention includes, within its scope, the pharmaceutical compositions comprising any of the possible isomers covered by the compounds of formula (I), both considered separately or in admixture, as well as the metabolites and the pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I).

10

In the present description, unless otherwise specified, with the term distamycin or distamycin-like framework R_2 we intend any moiety structurally closely related to distamycin itself, for instance by optionally replacing the ending amidino moiety of distamycin and/or its polypyrrole framework, or part of it, for instance as set forth below.

- 15 Protein kinases, hereinafter shortly referred to as PKs, are a large family of homologous proteins [see, for a reference, *J. Clin. Invest.* 105: 3 (2000); *Cancer Chemotherapy and Biological Response Modifiers, Annual 19* Chapter 11, 236 (2001)].

PKs, as components of signal transduction pathways, play a central role in diverse biological processes such as control of cell growth, metabolism, differentiation, and apoptosis. The development of selective PK inhibitors that can block or modulate diseases with defects in these signaling pathways, has been considered as a promising approach for the development of new anticancer drugs. A selection of these agents is shown in Table 1.

20
25

Table 1: Low Molecular weight ATP-competitive protein kinase inhibitors in clinical development

Target Kinase	Name
Bcr-Abl	STI571 (Gleevec; Imatinib)
EGF-R	ZD-1839 (Iressa) OSI-774 (Tarceva) PKI 166 EKB-569 GW572016
PKC/Trk	CEP 2563
PKC	UCN-01 GCP 41251 (STI 412) Safingol Perifosine
VEGF-R	SU 5416 (Semaxanib) CGP 79787 CP-564959 ZD 6474 ZD 2171 SU-11248
CDKs	Flavopiridol CI-202

- 5 The compositions of the invention may be thus comprised by the aforementioned acryloyl distamycin derivative of formula (I) and a protein kinase inhibitor, as listed in table 1.

According to a preferred embodiment of the invention, the PKs inhibitor is selected from STI571 (Gleevec; Imatinib - inhibitor of Bcr-Abl tyrosine kinase), ZD-1839 (Iressa - inhibitor of epidermal growth factor receptor 1 tyrosine kinase), OSI-774 (Tarceva - inhibitor of epidermal growth factor receptor 1 tyrosine kinase) and SU 5416 (Semaxanib - tyrosine kinase inhibitor that inhibits three distinct growth factor receptor targets).

- 15 According to another preferred embodiment of the invention, herewith provided are the above pharmaceutical compositions wherein, within the acryloyl distamycin derivative of formula (I), R₁ has the above reported meanings and R₂ is a group of formula (II)

below:



wherein

m is an integer from 0 to 2;

5 **n** is an integer from 2 to 5;

r is 0 or 1;


X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;

G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1
10 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR₃ wherein R₃ is hydrogen or C₁-C₄ alkyl;

B is selected from the group consisting of




wherein R₄ is cyano, amino, hydroxy or C₁-C₄ alkoxy; R₅, R₆ and R₇, the same or different, are hydrogen or C₁-C₄ alkyl.

In the present description, unless otherwise specified, with the term C₁-C₄ alkyl or

alkoxy group we intend a straight or branched group selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy.

Preferably, the pharmaceutical compositions of the invention comprise the above
5 acryloyl distamycin derivative of formula (I) wherein R_1 is bromine or chlorine; R_2 is the above group of formula (II) wherein r is 0, m is 0 or 1, n is 4 and B has the above reported meanings.

Still more preferred, within this class, are the pharmaceutical compositions comprising
10 the compounds of formula (I) wherein R_1 is bromine or chlorine; R_2 is the above group of formula (II) wherein r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:



wherein R_4 is cyano or hydroxy and R_5 , R_6 and R_7 , the same or different, are hydrogen
or C_1 - C_4 alkyl.

15 Pharmaceutically acceptable salts of the compounds of formula (I) are those with pharmaceutically acceptable inorganic or organic acids such as, for instance, hydrochloric, hydrobromic, sulfuric, nitric, acetic, propionic, succinic, malonic, citric, tartaric, methanesulfonic, p-toluenesulfonic acid and the like.

20 Examples of preferred acryloyl distamycin derivatives of formula (I), within the compositions object of the invention, for instance in the form of pharmaceutically acceptable salts, preferably with hydrochloric acid, are:

1. N-(5-[[[(5-[[[(5-[[[(2-[[amino(imino)methyl]amino]ethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;

2. N-(5-{{(5-{{(5-{{(2-{{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 5 3. N-(5-{{(5-{{(5-{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 10 4. N-(5-{{(5-{{(5-{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-imidazole-2-carboxamide hydrochloride;
- 15 5. N-(5-{{(5-{{(5-{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide hydrochloride;
6. N-(5-{{(5-{{(5-{{(3-amino-3-oxopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;
- 20 7. N-(5-{{(5-{{(5-{{(2-{{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
8. N-(5-{{(5-{{(3-{{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 25 9. N-(5-{{(5-{{(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and
- 30 10. N-{5-[(5-[(5-[(3-[(aminocarbonyl)amino]propyl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl}amino)carbonyl]-1-

methyl-1H-pyrrol-3-yl}-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

5 The above compounds of formula (I), either specifically identified as such or by means of the general formula, are known or easily prepared according to known methods as reported, for instance, in the aforementioned international patent applications WO 90/11277, WO 98/04524, WO 98/21202, WO 99/50265 and WO 99/50266 as well as in WO 01/40181.

10 The present invention further provides a product, otherwise referred to as kit of parts, comprising an acryloyl distamycin derivative of formula (I), as defined above, and a PK inhibitor, as a combined preparation for simultaneous, separate or sequential use in antitumor therapy.

15 A further aspect of the present invention is to provide a method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the above acryloyl distamycin derivative of formula (I) and a PK inhibitor, in amounts effective to produce a synergistic antineoplastic effect.

The present invention also provides a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in a mammal in need thereof, 20 including humans, the method comprising administering to said mammal a combined preparation comprising a PK inhibitor and an acryloyl distamycin derivative of formula (I), as defined above, in amounts effective to produce a synergistic antineoplastic effect.

By the term "synergistic antineoplastic effect", as used herein, it is meant the inhibition 25 of the growth tumor, preferably the complete regression of the tumor, by administering an effective amount of the combination comprising an acryloyl distamycin derivative of formula (I) and a PK inhibitor to mammals, including humans.

By the term "administered " or "administering", as used herein, it is meant parenteral and/or oral administration; the term "parenteral" means intravenous, subcutaneous and 30 intramuscular administration.

In the method of the present invention, the acryloyl distamycin derivative may be administered simultaneously with the PK inhibitor or, alternatively, both compounds may be administered sequentially in either order.

5 In this respect, it will be appreciated that the actual preferred method and order of administration will vary according to, inter alia, the particular formulation of the acryloyl distamycin of formula (I) being used, the particular formulation of the PK inhibitor being used, the particular tumor model being treated as well as the particular host being treated.

10 To administer the acryloyl distamycin derivative of formula (I), according to the method of the invention, the course of therapy generally employed comprises doses varying from about 0.05 to about 100 mg/m² of body surface area and, more preferably, from about 0.1 to about 50 mg/m² of body surface area.

For the administration of the PK inhibitor, according to the method of the invention, the course of therapy generally employed may be as follows.

15 For the administration of STI571 (Imatinib), doses varying from about 5 mg/day to about 5000 mg/day and, more preferably, from about 30 to about 1000 mg/day.

For the administration of ZD 1839 (Iressa) doses varying from about 5 mg/day to about 10000 mg/day and, more preferably, from about 50 to about 1000 mg/day.

20 For the administration of OSI-774 (Tarceva) doses varying from about 5 mg/day to about 10000 mg/day and, more preferably, from about 50 to about 1000 mg/day.

For the administration of SU 5416 (Semaxanib) doses varying from about 1 mg/m² to about 1000 mg/m² of body surface area and, more preferably, from about 10 to about 500 mg/m² of body surface area.

25 The antineoplastic therapy of the present invention is particularly suitable for treating breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors in mammals, including humans.

In a further aspect, the present invention is directed to a pharmaceutical composition comprising an effective amount of an acryloyl distamycin derivative of formula (I), as
30 defined above, and a PK inhibitor, in the preparation of a medicament for use in the


prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.

As the effect of an acryloyl distamycin derivative of formula (I) and a PK inhibitor is significantly increased without a parallel increase of toxicity, the combined therapy of
5 the present invention enhances the antitumoral effects of the acryloyl distamycin derivative and of the PK inhibitor and, hence, provides the most effective and least toxic treatment for tumors.

CLAIMS

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient,

5 - an acryloyl distamycin derivative of formula (I):



wherein:

R₁ is a bromine or chlorine atom;


10 R₂ is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and

- a protein kinase inhibitor.

2. A pharmaceutical composition according to claim 1 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, PKI 166,
15 EKB-569, GW572016, CEP 2563, UCN-01, GCP 41251 (STI 412), Safingol, Perifosine, SU 5416, CGP 79787, CP-564959, ZD 6474, ZD 2171, SU-11248, Flavopiridol, and CI-202.

3. A pharmaceutical composition according to claim 2 wherein the protein kinase
20 inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774 and SU 5416.

4. A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative of formula (I)




25

wherein:

R₁ is a bromine or chlorine atom;

R₂ is a group of formula (II)



wherein


m is an integer from 0 to 2;

5 n is an integer from 2 to 5;

r is 0 or 1;


X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;

10 G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR₃ wherein R₃ is hydrogen or C₁-C₄ alkyl;

B is selected from the group consisting of




15

wherein R₄ is cyano, amino, hydroxy or C₁-C₄ alkoxy; R₅, R₆ and R₇, the same or different, are hydrogen or C₁-C₄ alkyl.

5. A pharmaceutical composition according to claim 4 comprising an acryloyl

distamycin derivative of formula (I) wherein R_1 and R_2 are as defined in claim 4, r is 0, m is 0 or 1, n is 4, X and Y are both CH groups and B is selected from:



wherein R_4 is cyano or hydroxy and R_5 , R_6 and R_7 , the same or different, are hydrogen or $\text{C}_1\text{—C}_4$ alkyl.

6. A pharmaceutical composition according to claim 1 comprising an acryloyl distamycin derivative, optionally in the form of a pharmaceutically acceptable salt, selected from the group consisting of:

- 10 1. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 15 2. N-(5-{[(5-{[(5-{[(2-{[amino(imino)methyl]amino}propyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 20 3. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;
- 25 4. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-imidazole-2-carboxamide hydrochloride;
5. N-(5-{[(5-{[(5-{[(3-amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-

pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide hydrochloride;

6. N-(5-{{{(5-{{{(5-{{(3-amino-3-oxopropyl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)-3-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrazole-5-carboxamide;

7. N-(5-{{{(5-{{{(5-{{(2-{{amino(imino)methyl}amino}ethyl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-chloroacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;

8. N-(5-{{{(5-{{{(3-{{amino(imino)methyl}amino}propyl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;

9. N-(5-{{{(5-{{{(3-amino-3-iminopropyl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and


10. N-{5-[(5-[(5-[(3-[(aminocarbonyl)amino]propyl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)amino)carbonyl]-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient,

- N-(5-{{{(5-{{{(5-{{(2-{{amino(imino)methyl}amino}ethyl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)amino}carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and

- a protein kinase inhibitor selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416.

8. Products comprising an acryloyl distamycin derivative of formula (I):



wherein:


R_1 is a bromine or chlorine atom;

R_2 is a distamycin or distamycin-like framework; or a pharmaceutically acceptable salt thereof; and a protein kinase inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

9. Products according to claim 8 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, PKI 166, EKB-569, GW572016, CEP 2563, UCN-01, GCP 41251 (STI 412), Safingol, Perifosine, SU 5416, CGP 79787, CP-564959, ZD 6474, ZD 2171, SU-11248, Flavopiridol, and CI-202.

10. Products according to claim 9 wherein the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774 and SU 5416.


11. Products according to claim 8 comprising an acryloyl distamycin derivative of formula (I)



wherein:

R_1 is a bromine or chlorine atom;

R_2 is a group of formula (II)



wherein


m is an integer from 0 to 2;

n is an integer from 2 to 5;

r is 0 or 1;


- 5 X and Y are, the same or different and independently for each heterocyclic ring, a nitrogen atom or a CH group;

G is phenylene, a 5 or 6 membered saturated or unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of formula (III) below:



- 10 wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR₃ wherein R₃ is hydrogen or C₁-C₄ alkyl;

B is selected from the group consisting of



wherein R₄ is cyano, amino, hydroxy or C₁-C₄ alkoxy; R₅, R₆ and R₇, the same or different, are hydrogen or C₁-C₄ alkyl.

12. Products according to claim 8 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 6.

- 20 13. Products comprising the acryloyl distamycin derivative N-(5-[[[(5-[[[(5-[[[(2-[[amino(imino)methyl]amino]ethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride;

and a protein kinase inhibitor selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416; as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

5 14. Use of an acryloyl distamycin derivative of formula (I), as defined in claim 1, in the preparation of a medicament to be used in combination therapy with a protein kinase inhibitor, in the treatment of tumors.

10 15. Use according to claim 14 wherein the medicament further comprises the said protein kinase inhibitor.

16. Use according to claims 14 or 15 wherein the protein kinase inhibitor is as defined in claim 2.

15 17. Use according to claims 14 or 15 wherein the acryloyl distamycin derivative is selected from the group as defined in claim 6.

18. Use of the acryloyl distamycin derivative N-(5-{{(5-{{(5-{{(2-
20 {{amino(imino)methyl}amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-
yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-
yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; in
the preparation of a medicament to be used in combination therapy with a protein
kinase inhibitor selected from the group consisting of STI571, ZD-1839, OSI-774, and
SU 5416, in the treatment of tumors.

25

19. Use according to any one of claims from 14 to 18 wherein the tumor is selected from breast, ovary, lung, colon, kidney, stomach, pancreas, liver, melanoma, leukemia and brain tumors.

30 20. Use of an acryloyl distamycin derivative of formula (I), as defined in claim 1, in the preparation of a medicament to be used in combination therapy with a protein

kinase inhibitor, in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.

21. Use according to claim 20 wherein the medicament further comprises the said protein kinase inhibitor.

22. A method of treating a mammal, including humans, suffering from a neoplastic disease state, which method comprises administering to said mammal the acryloyl distamycin derivative of formula (I), as defined in claim 1, and a protein kinase inhibitor, in amounts effective to produce a synergistic antineoplastic effect.

23. A method according to claim 22 wherein the acryloyl distamycin derivative is N-(5-{{{5-{{{5-{{(2-[[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416.

24. A method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent, in a mammal in need thereof including humans, the method comprising administering to said mammal a combined preparation comprising a protein kinase inhibitor and an acryloyl distamycin derivative of formula (I), as defined in claim 1, in amounts effective to produce a synergistic antineoplastic effect.

25. A method according to claim 24 wherein the acryloyl distamycin derivative is N-(5-{{{5-{{{5-{{(2-[[amino(imino)methyl]amino}ethyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-4-[(2-bromoacryloyl)amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride; and the protein kinase inhibitor is selected from the group consisting of STI571, ZD-1839, OSI-774, and SU 5416.

ABSTRACT**COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED
ACRYLOYL DISTAMYCIN DERIVATIVES AND TYROSINE KINASE
5 INHIBITORS**

The present invention provides the combined use of acryloyl distamycin derivatives, in particular α -bromo- and α -chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and a protein kinase (seronine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations
10 in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.